IL1RN

Interleukin-1 receptor antagonist protein · P18510 · IL1RN on Sugi Atlas →

10,787 patent compounds predicted against IL1RN, 7,876 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL644843	0.57	10/20
SCHEMBL2184049	0.57	9/20
SCHEMBL1237981	0.67	8/20
SCHEMBL930562	0.57	8/20
SCHEMBL930564	0.57	8/20
SCHEMBL645270	0.59	7/20
SCHEMBL2192238	0.56	7/20
SCHEMBL1877671	0.54	6/20
SCHEMBL1877672	0.54	6/20
SCHEMBL1486271	0.61	5/20
SCHEMBL903409	0.54	5/20
SCHEMBL2191593	0.53	5/20
Hydrochloric Acid (SCHEMBL644842)	0.54	4/20
SCHEMBL2183858	0.52	4/20
Hydrochloric Acid (SCHEMBL930415)	0.51	4/20
Hydrochloric Acid (SCHEMBL930416)	0.51	4/20
Hydrochloric Acid (SCHEMBL930413)	0.50	4/20
Tryptophan (SCHEMBL294283)	0.42	4/20
SCHEMBL1718097	0.66	3/20
Hydrochloric Acid (SCHEMBL645269)	0.57	3/20

Clinical trials — most relevant to IL1RN by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease	PHASE3	COMPLETED
Preoperative Glucocorticoid Use in Major Hepatectomy	PHASE2/PHASE3	COMPLETED
Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)	PHASE2/PHASE3	COMPLETED
Anti-Interleukin-1 in Diabetes Action	PHASE2/PHASE3	COMPLETED
Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation	PHASE1/PHASE2	WITHDRAWN
Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation	PHASE1/PHASE2	WITHDRAWN
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)	PHASE2	COMPLETED
IL1-TRAP, Rilonacept, in Systemic Sclerosis	PHASE1/PHASE2	COMPLETED
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes	PHASE1/PHASE2	COMPLETED
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction	PHASE2	COMPLETED
Interleukin-1 Receptor Antagonist and Insulin Sensitivity	PHASE2	UNKNOWN
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy	PHASE1/PHASE2	UNKNOWN
Rilonacept for Treatment of Familial Mediterranean Fever (FMF)	PHASE2	COMPLETED
Anakinra as a Rescue Treatment for Allergic Inflammation	PHASE1/PHASE2	WITHDRAWN
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes	PHASE2	COMPLETED
Anakinra for Inflammatory Pustular Skin Diseases	PHASE2	COMPLETED
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors	PHASE1/PHASE2	COMPLETED
The Benefit of Bermekimab in Patients With Systemic Sclerosis	PHASE2	COMPLETED
Anakinra in Hidradenitis Suppurativa	PHASE2	COMPLETED
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy	PHASE1	COMPLETED
The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia	nan	NOT_YET_RECRUITING
Effects of Spinal Manipulative Treatment on Inflammatory Markers in Low Back Pain Patients	nan	COMPLETED
Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions	nan	RECRUITING
Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease	nan	COMPLETED
Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels	nan	RECRUITING
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk	nan	WITHDRAWN
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear	nan	UNKNOWN
Effects of IL-1β and Its Receptor Antagonists in the Treatment of Severe Infection and Inflammatory Storm in Children	nan	WITHDRAWN
Interleukin-34 in Stage I and II Periodontitis	nan	COMPLETED
IL1 Inhibition in FOP	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a IL1RN binder may also engage these)

Protein	Name	Similarity
Q866R8	—	1.000	Q866R8 →
P25085	—	1.000	P25085 →
P26890	—	1.000	P26890 →
O18999	—	1.000	O18999 →
Q9BEH0	—	0.995	Q9BEH0 →
O77482	—	0.994	O77482 →
Q29056	—	0.992	Q29056 →
Q9GMZ4	—	0.990	Q9GMZ4 →
P25086	—	0.989	P25086 →
Q9QYY1	—	0.986	Q9QYY1 →
IL36G	Interleukin-36 gamma	0.985	landscape →
Q9UHA7	—	0.985	Q9UHA7 →
Q9UBH0	—	0.982	Q9UBH0 →
Q8R460	—	0.980	Q8R460 →
Q9JLA2	—	0.980	Q9JLA2 →
Q9NZH6	—	0.973	Q9NZH6 →
Q9D6Z6	—	0.973	Q9D6Z6 →
Q9YGD3	—	0.962	Q9YGD3 →
P03969	—	0.960	P03969 →
P13109	—	0.960	P13109 →
P15655	—	0.959	P15655 →
Q92914	—	0.959	Q92914 →
P20003	—	0.959	P20003 →
P97636	—	0.959	P97636 →
Q2LKU9	—	0.959	Q2LKU9 →
Q7Z7L1	—	0.958	Q7Z7L1 →
PARP9	Protein mono-ADP-ribosyltransferase PARP9	0.958	landscape →
Q8QFQ8	—	0.957	Q8QFQ8 →
Q5RAV7	—	0.957	Q5RAV7 →
P70378	—	0.957	P70378 →